Medicine – Renal Osteodystrophy

Renal osteodystrophy refers specifically to the bone abnormalities that develop as a consequence of chronic kidney disease (CKD) and the associated disturbances of calcium, phosphate, vitamin D and parathyroid hormone metabolism.

It forms part of the broader condition called:

CKD–mineral and bone disorder (CKD-MBD).

CKD-MBD includes not only bone disease but also abnormalities of calcium, phosphate, PTH and vitamin D metabolism, together with vascular and soft-tissue calcification.

1. Basic Pathophysiology

As kidney function progressively declines, the kidneys become less able to:

Excrete phosphate.

Activate vitamin D.

Maintain normal calcium and phosphate balance.

These abnormalities stimulate:

Parathyroid hormone – PTH – secretion.

Persistent elevation of PTH produces:

Secondary hyperparathyroidism.

2. Normal Vitamin D Activation

Vitamin D obtained from the skin or diet is first converted in the liver to:

25-hydroxyvitamin D – 25(OH)D.

The kidney then converts this to the biologically active form:

1,25-dihydroxyvitamin D – 1,25(OH)₂D

also called:

Calcitriol.

This renal conversion is performed primarily by:

1α-hydroxylase.

3. Reduced Active Vitamin D in CKD

As functioning renal mass decreases, the ability of the kidney to produce:

Calcitriol

declines.

This is an important component of the mineral disturbance associated with advanced CKD.

4. Role of FGF23

An important modern addition to the traditional explanation is:

Fibroblast growth factor 23 – FGF23.

As phosphate retention begins, FGF23 levels increase.

FGF23 promotes renal phosphate excretion but also:

Suppresses renal calcitriol production.

Therefore, declining calcitriol can occur relatively early in CKD.

5. Effect of Low Calcitriol

Calcitriol normally promotes:

Intestinal calcium absorption.

When calcitriol levels fall, intestinal calcium absorption decreases.

This contributes to:

Hypocalcaemia or a tendency toward lower ionised calcium.

6. Calcium Malabsorption

The original note states:

“Malabsorption of calcium.”

More precisely, CKD causes:

Reduced intestinal calcium absorption

largely because of reduced active vitamin D activity.

This contributes to stimulation of the parathyroid glands.

7. Phosphate Retention

Normal kidneys excrete excess phosphate.

As GFR falls, phosphate excretion becomes progressively impaired.

This leads eventually to:

Phosphate retention

and, particularly in advanced CKD:

Hyperphosphataemia.

8. Hyperphosphataemia and Calcium

Increased phosphate contributes to disturbances in calcium balance and directly stimulates mechanisms promoting:

Secondary hyperparathyroidism.

Therefore, phosphate retention is a central component of CKD-MBD.

9. Secondary Hyperparathyroidism

The parathyroid glands respond to CKD-related biochemical disturbances by increasing:

PTH secretion.

This is called:

Secondary hyperparathyroidism.

The parathyroid glands are responding appropriately to an abnormal physiological environment rather than functioning autonomously initially.

10. Causes of Increased PTH in CKD

Important stimuli include:

Reduced ionised calcium.

Phosphate retention and hyperphosphataemia.

Reduced calcitriol.

Reduced activation of the calcium-sensing receptor and vitamin D receptor pathways.

With persistent stimulation, the parathyroid glands undergo:

Hyperplasia.

11. Role of Acidosis

The original notes also list:

Acidosis.

Chronic metabolic acidosis can contribute to:

Bone mineral loss

and

Abnormal bone metabolism.

However, the principal drivers of secondary hyperparathyroidism are the disturbances involving:

Phosphate, calcium, calcitriol and parathyroid regulation.

12. PTH and Bone

Persistently elevated PTH increases:

Bone turnover.

Bone resorption and remodelling become excessive.

The classical high-turnover bone lesion associated with severe secondary hyperparathyroidism is:

Osteitis fibrosa.

13. Osteitis Fibrosa

Osteitis fibrosa results from prolonged excessive PTH activity.

There is:

Increased osteoclastic bone resorption.

Increased bone turnover.

Replacement of some bone by fibrous tissue.

Severe disease may produce characteristic skeletal abnormalities.

14. Brown Tumours

Severe hyperparathyroidism can occasionally produce:

Brown tumours.

These are not true neoplasms.

They represent focal areas of:

Bone resorption, fibrosis, haemorrhage and giant-cell accumulation.

They are now uncommon with appropriate CKD management.

15. Osteomalacia

Another possible component of renal osteodystrophy is:

Osteomalacia.

Osteomalacia means:

Defective mineralisation of newly formed bone matrix.

Historically, aluminium toxicity in dialysis patients was an important cause, although this is much less common with modern dialysis practice.

16. Adynamic Bone Disease

An important modern category not included in the original notes is:

Adynamic bone disease.

This is a:

Low-turnover bone disorder

in which bone formation and resorption are both reduced.

It can occur when PTH activity is excessively suppressed, particularly in some patients receiving dialysis.

17. Why Excessive PTH Suppression Can Be Harmful

PTH should not simply be reduced as much as possible.

Excessive suppression can contribute to:

Adynamic bone disease.

Therefore, CKD-MBD treatment aims for appropriate control of mineral metabolism rather than complete elimination of PTH secretion.

18. Osteoporosis

Patients with CKD can also develop:

Osteoporosis

with reduced bone strength and increased fracture risk.

However, osteoporosis and renal osteodystrophy are not exactly synonymous.

A patient with CKD may have both:

CKD-related abnormalities of bone turnover/mineralisation

and

Osteoporosis.

19. Major Patterns of Renal Osteodystrophy

Renal osteodystrophy can therefore include different patterns:

High-turnover bone disease due to secondary hyperparathyroidism.

Osteomalacia due to defective mineralisation.

Adynamic low-turnover bone disease.

Mixed uraemic osteodystrophy.

These patterns are more precise than simply describing all renal bone disease as osteoporosis.

20. Clinical Features

Many patients initially have:

No obvious skeletal symptoms.

More advanced disease can cause:

Bone pain.

Muscle weakness.

Skeletal deformity.

Fragility fractures.

Growth abnormalities in children.

21. Fractures

Abnormal bone turnover and mineralisation increase the risk of:

Fragility fractures.

Fracture risk may be further increased by:

Older age.

Corticosteroid exposure.

Reduced physical activity.

Malnutrition.

Coexisting osteoporosis.

22. Osteosclerosis

Renal osteodystrophy can sometimes produce areas of:

Osteosclerosis.

A classic radiological example is:

Rugger-jersey spine.

23. Rugger-Jersey Spine

The rugger-jersey spine describes bands of increased bone density along the superior and inferior vertebral endplates.

The vertebral body develops alternating:

Dense

and

Less dense

areas.

The appearance resembles the horizontal stripes of a rugby jersey.

24. Other Radiological Features

Severe secondary hyperparathyroidism may produce:

Subperiosteal bone resorption.

This is particularly characteristic along the:

Radial aspects of the middle phalanges.

Other abnormalities can include:

Bone cyst-like lesions.

Osteosclerosis.

Fractures.

25. Skull Changes

Severe hyperparathyroid bone disease can produce a:

“Salt-and-pepper” skull appearance.

This results from diffuse abnormalities of skull mineralisation.

26. Laboratory Assessment

Evaluation of CKD-MBD commonly includes measurement of:

Serum calcium.

Serum phosphate.

PTH.

Alkaline phosphatase.

25-hydroxyvitamin D.

These values should be interpreted together rather than relying on a single measurement.

27. Typical Biochemical Pattern

In advanced untreated CKD with secondary hyperparathyroidism, a typical pattern may include:

Raised phosphate.

Normal or low calcium.

Raised PTH.

Reduced calcitriol.

Raised alkaline phosphatase when bone turnover is high.

However, the biochemical pattern varies with CKD stage and treatment.

28. Treatment Principles

Management of renal osteodystrophy is part of the broader treatment of:

CKD-MBD.

The major goals are to control:

Phosphate balance.

Calcium balance.

Vitamin D abnormalities.

Secondary hyperparathyroidism.

Metabolic acidosis where present.

29. Dietary Phosphate Control

The first step in controlling phosphate may include:

Dietary phosphate restriction or modification.

Particular attention may be given to highly absorbable phosphate from:

Processed foods containing phosphate additives.

Management should avoid unnecessary nutritional restriction.

30. Phosphate Binders

If phosphate remains elevated, patients may require:

Phosphate binders.

These drugs bind dietary phosphate in the gastrointestinal tract and reduce its:

Intestinal absorption.

They are generally taken:

With meals.

31. Calcium-Based Phosphate Binders

An example is:

Calcium acetate.

Another is:

Calcium carbonate.

These reduce phosphate absorption but also provide calcium.

32. Limitations of Calcium-Based Binders

Excessive calcium exposure can contribute to:

Hypercalcaemia

and potentially:

Vascular and soft-tissue calcification.

Therefore, non-calcium-containing phosphate binders may be preferred in selected patients.

33. Non-Calcium Phosphate Binders

Examples include:

Sevelamer

and

Lanthanum carbonate.

These lower phosphate without adding a substantial calcium load.

The appropriate binder depends on the individual patient’s biochemical profile.

34. Vitamin D Treatment

The original notes mention:

1-alfacalcidol.

The correct drug name is:

Alfacalcidol.

Alfacalcidol is a vitamin D analogue that can be converted by the liver to an active vitamin D compound without requiring normal renal 1α-hydroxylation.

35. Active Vitamin D Therapy

Agents used in selected CKD patients include:

Calcitriol

and

Vitamin D analogues such as alfacalcidol.

These can suppress:

Excessive PTH secretion.

However, they must be used carefully because they can increase:

Calcium

and

phosphate.

36. Nutritional Vitamin D

Patients may also have ordinary vitamin D deficiency.

Therefore:

25-hydroxyvitamin D deficiency

may require treatment with nutritional vitamin D according to the clinical situation.

This should be distinguished from the impaired renal production of:

Calcitriol.

37. Calcimimetics

An important modern treatment not included in the original notes is:

Calcimimetic therapy.

An important example is:

Cinacalcet.

Calcimimetics increase the sensitivity of the parathyroid:

Calcium-sensing receptor.

This suppresses:

PTH secretion.

38. Cinacalcet

Cinacalcet is particularly useful for controlling:

Secondary hyperparathyroidism in selected dialysis patients.

An important adverse effect is:

Hypocalcaemia.

Therefore calcium must be monitored.

39. Correction of Metabolic Acidosis

Persistent metabolic acidosis can adversely affect:

Bone metabolism

and

Muscle function.

Appropriate correction of chronic metabolic acidosis may therefore form part of overall CKD management.

40. Parathyroidectomy

If severe secondary hyperparathyroidism remains uncontrolled despite appropriate medical therapy, treatment may require:

Parathyroidectomy.

This is generally reserved for:

Severe, persistent or refractory hyperparathyroidism.

41. Tertiary Hyperparathyroidism

After prolonged secondary hyperparathyroidism, the enlarged parathyroid glands may eventually begin secreting PTH relatively autonomously.

This is called:

Tertiary hyperparathyroidism.

42. Secondary versus Tertiary Hyperparathyroidism

Secondary hyperparathyroidism:

PTH rises appropriately in response to CKD-related disturbances.

Calcium is often normal or low.

Tertiary hyperparathyroidism:

Long-standing parathyroid hyperplasia becomes relatively autonomous.

PTH remains markedly elevated.

Hypercalcaemia may develop.

This can occur in patients with longstanding advanced CKD, including some patients after successful kidney transplantation.

43. Parathyroidectomy in Severe Disease

Surgery may be considered when severe hyperparathyroidism causes persistent:

Very high PTH.

Hypercalcaemia or hyperphosphataemia.

Bone disease.

Other complications

despite appropriate medical treatment.

44. Vascular Calcification

CKD-MBD does not affect only the skeleton.

Disturbances of calcium and phosphate metabolism can contribute to:

Vascular calcification.

This is one reason excessive phosphate and calcium exposure are clinically important.

45. Soft-Tissue Calcification

Calcium-phosphate deposition may also occur in:

Soft tissues.

In severe cases, abnormalities of mineral metabolism can contribute to serious complications such as:

Calciphylaxis,

particularly in patients with advanced CKD.

46. Renal Osteodystrophy – Pathophysiology Note Form

CKD → reduced phosphate excretion.

Phosphate retention → increased FGF23 and eventually hyperphosphataemia.

CKD + increased FGF23 → reduced calcitriol.

Reduced calcitriol → reduced intestinal calcium absorption.

Lower calcium + phosphate abnormalities + reduced calcitriol → increased PTH.

Persistent increased PTH → secondary hyperparathyroidism.

Secondary hyperparathyroidism → increased bone turnover and osteitis fibrosa.

47. Renal Osteodystrophy – Bone Changes Note Form

High-turnover disease:

Secondary hyperparathyroidism.

Osteitis fibrosa.

Subperiosteal bone resorption.

Defective mineralisation:

Osteomalacia.

Low-turnover disease:

Adynamic bone disease.

Osteosclerosis:

Rugger-jersey spine.

Other skeletal manifestations:

Bone pain.

Weakness.

Fragility fractures.

Skeletal deformity.

48. Renal Osteodystrophy – Treatment Note Form

Control phosphate:

Dietary measures.

Phosphate binders.

Calcium acetate or calcium carbonate in selected patients.

Sevelamer or lanthanum as non-calcium alternatives.

Correct vitamin D abnormalities:

Treat nutritional vitamin D deficiency when appropriate.

Active vitamin D or analogues such as calcitriol or alfacalcidol in selected patients.

Control excessive PTH:

Vitamin D receptor activation when appropriate.

Calcimimetics such as cinacalcet in selected dialysis patients.

Treat refractory severe hyperparathyroidism:

Parathyroidectomy.

Correct associated abnormalities:

Metabolic acidosis.

Calcium disturbances.

Other CKD-related metabolic problems.

49. Important Corrections to the Original Notes

The original definition:

“Bone disease resulting from metabolic disturbance in renal failure”

is broadly correct, but modern terminology distinguishes:

RENAL OSTEODYSTROPHY = THE BONE COMPONENT

from:

CKD-MBD = THE BROADER SYSTEMIC MINERAL AND BONE DISORDER.

The statement:

“Low ionised calcium is caused by lack of 1,25-dihydroxyvitamin D”

is broadly correct but incomplete.

Modern understanding also emphasises:

FGF23 elevation

and

phosphate retention.

The term:

“Malabsorption of calcium”

is better expressed as:

REDUCED INTESTINAL CALCIUM ABSORPTION DUE TO REDUCED ACTIVE VITAMIN D ACTIVITY.

The original treatment:

“Vitamin D – 1-alfacalcidol”

should be corrected to:

ALFACALCIDOL

and active vitamin D therapy should be used selectively because excessive treatment may cause:

Hypercalcaemia, hyperphosphataemia and excessive PTH suppression.

The original treatment list should also include the important modern option:

CALCIMIMETICS, SUCH AS CINACALCET,

for selected patients with secondary hyperparathyroidism.

Key Clinical Pattern

The central pathway is:

CKD → PHOSPHATE RETENTION + ↓ CALCITRIOL → ↓ CALCIUM SIGNAL → ↑ PTH → SECONDARY HYPERPARATHYROIDISM → ABNORMAL BONE TURNOVER.

Remember the classic findings:

↑ PHOSPHATE

↓/NORMAL CALCIUM

↓ CALCITRIOL

↑ PTH

± ↑ ALKALINE PHOSPHATASE

The classic skeletal association is:

SECONDARY HYPERPARATHYROIDISM → OSTEOITIS FIBROSA.

The classic radiological sign is:

RUGGER-JERSEY SPINE.

And the major treatment principles are:

CONTROL PHOSPHATE + MANAGE VITAMIN D + CONTROL PTH + PARATHYROIDECTOMY IF SEVERE AND REFRACTORY.

1. Basic Pathophysiology As kidney function progressively declines, the kidneys become less able to: Excrete phosphate. Activate vitamin D. Maintain normal calcium and phosphate balance. These abnormalities stimulate: Parathyroid hormone – PTH – secretion. Persistent elevation of PTH produces: Secondary hyperparathyroidism. 

2. Normal Vitamin D Activation Vitamin D obtained from the skin or diet is first converted in the liver to: 25-hydroxyvitamin D – 25(OH)D. The kidney then converts this to the biologically active form: 1,25-dihydroxyvitamin D – 1,25(OH)₂D also called: Calcitriol. This renal conversion is performed primarily by: 1α-hydroxylase. 

3. Reduced Active Vitamin D in CKD As functioning renal mass decreases, the ability of the kidney to produce: Calcitriol declines. This is an important component of the mineral disturbance associated with advanced CKD. 

4. Role of FGF23 An important modern addition to the traditional explanation is: Fibroblast growth factor 23 – FGF23. As phosphate retention begins, FGF23 levels increase. FGF23 promotes renal phosphate excretion but also: Suppresses renal calcitriol production. Therefore, declining calcitriol can occur relatively early in CKD. 

5. Effect of Low Calcitriol Calcitriol normally promotes: Intestinal calcium absorption. When calcitriol levels fall, intestinal calcium absorption decreases. This contributes to: Hypocalcaemia or a tendency toward lower ionised calcium. 

6. Calcium Malabsorption The original note states: “Malabsorption of calcium.” More precisely, CKD causes: Reduced intestinal calcium absorption largely because of reduced active vitamin D activity. This contributes to stimulation of the parathyroid glands. 

7. Phosphate Retention Normal kidneys excrete excess phosphate. As GFR falls, phosphate excretion becomes progressively impaired. This leads eventually to: Phosphate retention and, particularly in advanced CKD: Hyperphosphataemia. 

8. Hyperphosphataemia and Calcium Increased phosphate contributes to disturbances in calcium balance and directly stimulates mechanisms promoting: Secondary hyperparathyroidism. Therefore, phosphate retention is a central component of CKD-MBD. 

9. Secondary Hyperparathyroidism The parathyroid glands respond to CKD-related biochemical disturbances by increasing: PTH secretion. This is called: Secondary hyperparathyroidism. The parathyroid glands are responding appropriately to an abnormal physiological environment rather than functioning autonomously initially. 

10. Causes of Increased PTH in CKD Important stimuli include: Reduced ionised calcium. Phosphate retention and hyperphosphataemia. Reduced calcitriol. Reduced activation of the calcium-sensing receptor and vitamin D receptor pathways. With persistent stimulation, the parathyroid glands undergo: Hyperplasia. 

11. Role of Acidosis The original notes also list: Acidosis. Chronic metabolic acidosis can contribute to: Bone mineral loss and Abnormal bone metabolism. However, the principal drivers of secondary hyperparathyroidism are the disturbances involving: Phosphate, calcium, calcitriol and parathyroid regulation. 

12. PTH and Bone Persistently elevated PTH increases: Bone turnover. Bone resorption and remodelling become excessive. The classical high-turnover bone lesion associated with severe secondary hyperparathyroidism is: Osteitis fibrosa. 

13. Osteitis Fibrosa Osteitis fibrosa results from prolonged excessive PTH activity. There is: Increased osteoclastic bone resorption. Increased bone turnover. Replacement of some bone by fibrous tissue. Severe disease may produce characteristic skeletal abnormalities. 

14. Brown Tumours Severe hyperparathyroidism can occasionally produce: Brown tumours. These are not true neoplasms. They represent focal areas of: Bone resorption, fibrosis, haemorrhage and giant-cell accumulation. They are now uncommon with appropriate CKD management. 

15. Osteomalacia Another possible component of renal osteodystrophy is: Osteomalacia. Osteomalacia means: Defective mineralisation of newly formed bone matrix. Historically, aluminium toxicity in dialysis patients was an important cause, although this is much less common with modern dialysis practice. 

16. Adynamic Bone Disease An important modern category not included in the original notes is: Adynamic bone disease. This is a: Low-turnover bone disorder in which bone formation and resorption are both reduced. It can occur when PTH activity is excessively suppressed, particularly in some patients receiving dialysis. 

17. Why Excessive PTH Suppression Can Be Harmful PTH should not simply be reduced as much as possible. Excessive suppression can contribute to: Adynamic bone disease. Therefore, CKD-MBD treatment aims for appropriate control of mineral metabolism rather than complete elimination of PTH secretion. 

18. Osteoporosis Patients with CKD can also develop: Osteoporosis with reduced bone strength and increased fracture risk. However, osteoporosis and renal osteodystrophy are not exactly synonymous. A patient with CKD may have both: CKD-related abnormalities of bone turnover/mineralisation and Osteoporosis. 

19. Major Patterns of Renal Osteodystrophy Renal osteodystrophy can therefore include different patterns: High-turnover bone disease due to secondary hyperparathyroidism. Osteomalacia due to defective mineralisation. Adynamic low-turnover bone disease. Mixed uraemic osteodystrophy. These patterns are more precise than simply describing all renal bone disease as osteoporosis. 

20. Clinical Features Many patients initially have: No obvious skeletal symptoms. More advanced disease can cause: Bone pain. Muscle weakness. Skeletal deformity. Fragility fractures. Growth abnormalities in children. 

21. Fractures Abnormal bone turnover and mineralisation increase the risk of: Fragility fractures. Fracture risk may be further increased by: Older age. Corticosteroid exposure. Reduced physical activity. Malnutrition. Coexisting osteoporosis. 

22. Osteosclerosis Renal osteodystrophy can sometimes produce areas of: Osteosclerosis. A classic radiological example is: Rugger-jersey spine. 

23. Rugger-Jersey Spine The rugger-jersey spine describes bands of increased bone density along the superior and inferior vertebral endplates. The vertebral body develops alternating: Dense and Less dense areas. The appearance resembles the horizontal stripes of a rugby jersey. 

24. Other Radiological Features Severe secondary hyperparathyroidism may produce: Subperiosteal bone resorption. This is particularly characteristic along the: Radial aspects of the middle phalanges. Other abnormalities can include: Bone cyst-like lesions. Osteosclerosis. Fractures. 

25. Skull Changes Severe hyperparathyroid bone disease can produce a: “Salt-and-pepper” skull appearance. This results from diffuse abnormalities of skull mineralisation. 

26. Laboratory Assessment Evaluation of CKD-MBD commonly includes measurement of: Serum calcium. Serum phosphate. PTH. Alkaline phosphatase. 25-hydroxyvitamin D. These values should be interpreted together rather than relying on a single measurement. 

27. Typical Biochemical Pattern In advanced untreated CKD with secondary hyperparathyroidism, a typical pattern may include: Raised phosphate. Normal or low calcium. Raised PTH. Reduced calcitriol. Raised alkaline phosphatase when bone turnover is high. However, the biochemical pattern varies with CKD stage and treatment. 

28. Treatment Principles Management of renal osteodystrophy is part of the broader treatment of: CKD-MBD. The major goals are to control: Phosphate balance. Calcium balance. Vitamin D abnormalities. Secondary hyperparathyroidism. Metabolic acidosis where present. 

29. Dietary Phosphate Control The first step in controlling phosphate may include: Dietary phosphate restriction or modification. Particular attention may be given to highly absorbable phosphate from: Processed foods containing phosphate additives. Management should avoid unnecessary nutritional restriction. 

30. Phosphate Binders If phosphate remains elevated, patients may require: Phosphate binders. These drugs bind dietary phosphate in the gastrointestinal tract and reduce its: Intestinal absorption. They are generally taken: With meals. 

31. Calcium-Based Phosphate Binders An example is: Calcium acetate. Another is: Calcium carbonate. These reduce phosphate absorption but also provide calcium. 

32. Limitations of Calcium-Based Binders Excessive calcium exposure can contribute to: Hypercalcaemia and potentially: Vascular and soft-tissue calcification. Therefore, non-calcium-containing phosphate binders may be preferred in selected patients. 

33. Non-Calcium Phosphate Binders Examples include: Sevelamer and Lanthanum carbonate. These lower phosphate without adding a substantial calcium load. The appropriate binder depends on the individual patient’s biochemical profile. 

34. Vitamin D Treatment The original notes mention: 1-alfacalcidol. The correct drug name is: Alfacalcidol. Alfacalcidol is a vitamin D analogue that can be converted by the liver to an active vitamin D compound without requiring normal renal 1α-hydroxylation. 

35. Active Vitamin D Therapy Agents used in selected CKD patients include: Calcitriol and Vitamin D analogues such as alfacalcidol. These can suppress: Excessive PTH secretion. However, they must be used carefully because they can increase: Calcium and phosphate. 

36. Nutritional Vitamin D Patients may also have ordinary vitamin D deficiency. Therefore: 25-hydroxyvitamin D deficiency may require treatment with nutritional vitamin D according to the clinical situation. This should be distinguished from the impaired renal production of: Calcitriol. 

37. Calcimimetics An important modern treatment not included in the original notes is: Calcimimetic therapy. An important example is: Cinacalcet. Calcimimetics increase the sensitivity of the parathyroid: Calcium-sensing receptor. This suppresses: PTH secretion. 

38. Cinacalcet Cinacalcet is particularly useful for controlling: Secondary hyperparathyroidism in selected dialysis patients. An important adverse effect is: Hypocalcaemia. Therefore calcium must be monitored. 

39. Correction of Metabolic Acidosis Persistent metabolic acidosis can adversely affect: Bone metabolism and Muscle function. Appropriate correction of chronic metabolic acidosis may therefore form part of overall CKD management. 

40. Parathyroidectomy If severe secondary hyperparathyroidism remains uncontrolled despite appropriate medical therapy, treatment may require: Parathyroidectomy. This is generally reserved for: Severe, persistent or refractory hyperparathyroidism. 

41. Tertiary Hyperparathyroidism After prolonged secondary hyperparathyroidism, the enlarged parathyroid glands may eventually begin secreting PTH relatively autonomously. This is called: Tertiary hyperparathyroidism. 

42. Secondary versus Tertiary Hyperparathyroidism Secondary hyperparathyroidism: PTH rises appropriately in response to CKD-related disturbances. Calcium is often normal or low. 

Tertiary hyperparathyroidism: Long-standing parathyroid hyperplasia becomes relatively autonomous. PTH remains markedly elevated. Hypercalcaemia may develop. This can occur in patients with longstanding advanced CKD, including some patients after successful kidney transplantation. 

43. Parathyroidectomy in Severe Disease Surgery may be considered when severe hyperparathyroidism causes persistent: Very high PTH. Hypercalcaemia or hyperphosphataemia. Bone disease. Other complications despite appropriate medical treatment. 

44. Vascular Calcification CKD-MBD does not affect only the skeleton. Disturbances of calcium and phosphate metabolism can contribute to: Vascular calcification. This is one reason excessive phosphate and calcium exposure are clinically important. 

45. Soft-Tissue Calcification Calcium-phosphate deposition may also occur in: Soft tissues. In severe cases, abnormalities of mineral metabolism can contribute to serious complications such as: Calciphylaxis, particularly in patients with advanced CKD. 

46. Renal Osteodystrophy – Pathophysiology Note Form CKD → reduced phosphate excretion. 

Phosphate retention → increased FGF23 and eventually hyperphosphataemia. 

CKD + increased FGF23 → reduced calcitriol. 

Reduced calcitriol → reduced intestinal calcium absorption. 

Lower calcium + phosphate abnormalities + reduced calcitriol → increased PTH. 

Persistent increased PTH → secondary hyperparathyroidism. 

Secondary hyperparathyroidism → increased bone turnover and osteitis fibrosa. 

47. Renal Osteodystrophy – Bone Changes Note Form High-turnover disease: Secondary hyperparathyroidism. Osteitis fibrosa. Subperiosteal bone resorption. 

Defective mineralisation: Osteomalacia. 

Low-turnover disease: Adynamic bone disease. 

Osteosclerosis: Rugger-jersey spine. 

Other skeletal manifestations: Bone pain. Weakness. Fragility fractures. Skeletal deformity. 

48. Renal Osteodystrophy – Treatment Note Form Control phosphate: Dietary measures. Phosphate binders. Calcium acetate or calcium carbonate in selected patients. Sevelamer or lanthanum as non-calcium alternatives. 

Correct vitamin D abnormalities: Treat nutritional vitamin D deficiency when appropriate. Active vitamin D or analogues such as calcitriol or alfacalcidol in selected patients. 

Control excessive PTH: Vitamin D receptor activation when appropriate. Calcimimetics such as cinacalcet in selected dialysis patients. 

Treat refractory severe hyperparathyroidism: Parathyroidectomy. 

Correct associated abnormalities: Metabolic acidosis. Calcium disturbances. Other CKD-related metabolic problems. 

49. Important Corrections to the Original Notes The original definition: “Bone disease resulting from metabolic disturbance in renal failure” is broadly correct, but modern terminology distinguishes: RENAL OSTEODYSTROPHY = THE BONE COMPONENT from: CKD-MBD = THE BROADER SYSTEMIC MINERAL AND BONE DISORDER. 

The statement: “Low ionised calcium is caused by lack of 1,25-dihydroxyvitamin D” is broadly correct but incomplete. Modern understanding also emphasises: FGF23 elevation and phosphate retention. 

The term: “Malabsorption of calcium” is better expressed as: REDUCED INTESTINAL CALCIUM ABSORPTION DUE TO REDUCED ACTIVE VITAMIN D ACTIVITY. 

The original treatment: “Vitamin D – 1-alfacalcidol” should be corrected to: ALFACALCIDOL and active vitamin D therapy should be used selectively because excessive treatment may cause: Hypercalcaemia, hyperphosphataemia and excessive PTH suppression. 

The original treatment list should also include the important modern option: CALCIMIMETICS, SUCH AS CINACALCET, for selected patients with secondary hyperparathyroidism. 

Key Clinical Pattern The central pathway is: CKD → PHOSPHATE RETENTION + ↓ CALCITRIOL → ↓ CALCIUM SIGNAL → ↑ PTH → SECONDARY HYPERPARATHYROIDISM → ABNORMAL BONE TURNOVER. Remember the classic findings: ↑ PHOSPHATE ↓/NORMAL CALCIUM ↓ CALCITRIOL ↑ PTH ± ↑ ALKALINE PHOSPHATASE 

The classic skeletal association is: SECONDARY HYPERPARATHYROIDISM → OSTEOITIS FIBROSA. The classic radiological sign is: RUGGER-JERSEY SPINE. And the major treatment principles are: CONTROL PHOSPHATE + MANAGE VITAMIN D + CONTROL PTH + PARATHYROIDECTOMY IF SEVERE AND REFRACTORY.